 The present study is planned to evaluate the effect of the aclidinium bromideformoterol fumarate 40012 μg FDC BID on the hyperinflation, exercise endurance and physical activity in patients with moderate to severe COPD. Additionally, the effect of the behavioural intervention on top of aclidinium bromideformoterol fumarate 40012 μg will be assessed both on the exercise endurance and the physical activity. 